This is a major pipeline catalyst that could transform Telix's imaging franchise by opening a much larger addressable market in initial prostate cancer diagnosis. Traders should monitor for BiPASS top-line data readout and subsequent NDA submission, as positive results could drive significant revenue expansion beyond current staging indications.
Price Chart
Executive Summary
Telix Pharmaceuticals completed enrollment of 350 patients in the Phase 3 BiPASS study of Illuccix and Gozellix for prostate cancer imaging in the pre-biopsy setting. The company also aligned with the FDA on an NDA pathway that, if approved, would support new product reimbursement and broaden patient access. This is a significant clinical milestone that could expand Telix's addressable market substantially if the study meets its primary objectives.
Key Facts
- Completed enrollment of 350 patients in the Phase 3 BiPASS study
- Aligned with FDA on an NDA pathway for BiPASS that would support new product reimbursement
- BiPASS is the first registrational study of 68Ga-PSMA-PET imaging in the pre-biopsy setting
- Prior PRIMARY and PRIMARY2 studies demonstrated combining PSMA-PET with MRI can reduce unnecessary biopsies by almost 50%
- Globally, more than 3 million prostate biopsies are performed annually, with up to 75% found to be negative
Financial Impact
Potential to expand PSMA-PET imaging from current staging/re-staging use to a substantially larger pre-biopsy patient population, representing a new clinical application with a dedicated reimbursement pathway
Risk Factors
- BiPASS study may not meet its primary endpoints
- FDA may not approve the NDA even if endpoints are met
- Competing imaging modalities or diagnostic approaches could emerge
- Reimbursement may be less favorable than anticipated
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-059952 |
| Document: a20260902bipasscompletio.htm | 0001628280-26-059952 |
| Document: 0001628280-26-059952-index-headers.html | 0001628280-26-059952 |
| Document: 0001628280-26-059952-index.html | 0001628280-26-059952 |
| Document: 0001628280-26-059952.txt | 0001628280-26-059952 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $12.83 $11.95 | ▼ −6.86% | ▼ −8.99% | $10.55 (−17.77%) |
Sep 14, 2026 18d ago | Press Release | $11.78 $11.31 | ▼ −3.99% | ▼ −4.10% | $10.55 (−10.44%) |
Sep 2, 2026 4w ago | 6-K | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Sep 1, 2026 4w ago | Press Release | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Aug 20, 2026 6w ago | 6-K | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Aug 20, 2026 6w ago | Press Release | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Jul 30, 2026 9w ago | Press Release | $9.89 $11.52 | ▲ +16.48% | ▲ +12.97% | $10.55 (+6.67%) |
Jul 21, 2026 10w ago | Press Release | $10.32 $10.10 | ▼ −2.13% | ▲ +0.27% | $10.55 (+2.23%) |
Jul 21, 2026 10w ago | 6-K | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
Jul 20, 2026 10w ago | Press Release | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access